Sort   by:  
 Page size 
UnknownTolerability, Safety, Pharmacokinetics, and Immunogenicity of a Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab, in Chinese Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study.
Not available
S-EPMC8284438 | biostudies-literature
UnknownFlat dose regimen of toripalimab based on model-informed drug development approach.
Not available
S-EPMC9880172 | biostudies-literature
UnknownToripalimab combined with bevacizumab plus chemotherapy as first-line treatment for refractory recurrent or metastatic cervical cancer: a single-arm, open-label, phase II study (JS001-ISS-CO214).
Not available
S-EPMC12099045 | biostudies-literature
UnknownQuality comparability assessment of a SARS-CoV-2-neutralizing antibody across transient, mini-pool-derived and single-clone CHO cells.
Not available
S-EPMC8726686 | biostudies-literature
UnknownAxitinib in Combination With Toripalimab, a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial.
Not available
S-EPMC6839911 | biostudies-literature
UnknownNeoadjuvant anthracycline followed by toripalimab combined with nab-paclitaxel in patients with early triple-negative breast cancer (NeoTENNIS): a single-arm, phase II study.
Not available
S-EPMC11260571 | biostudies-literature
UnknownEtesevimab in combination with JS026 neutralizing SARS-CoV-2 and its variants.
Not available
S-EPMC8843163 | biostudies-literature
UnknownClinical pharmacokinetics and pharmacodynamics of ongericimab: A potential long-acting PCSK9 monoclonal antibody in healthy subjects and patients with hypercholesterolemia: Randomized, double-blind, placebo-controlled phase Ia and Ib/II studies.
Not available
S-EPMC11536336 | biostudies-literature
UnknownOral remdesivir derivative VV116 is a potent inhibitor of respiratory syncytial virus with efficacy in mouse model.
Not available
S-EPMC9012943 | biostudies-literature
UnknownShort-course radiotherapy combined with chemotherapy and PD-1 inhibitor in low-lying early rectal cancer: study protocol for a single-arm, multicentre, prospective, phase II trial (TORCH-E).
Not available
S-EPMC10565143 | biostudies-literature
Sort   by:  
 Page size